These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 12384804)
1. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805 [TBL] [Abstract][Full Text] [Related]
3. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Benlalam H; Vignard V; Khammari A; Bonnin A; Godet Y; Pandolfino MC; Jotereau F; Dreno B; Labarrière N Cancer Immunol Immunother; 2007 Apr; 56(4):515-26. PubMed ID: 16874485 [TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial. Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033 [TBL] [Abstract][Full Text] [Related]
6. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267 [TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243 [TBL] [Abstract][Full Text] [Related]
8. Tissue biomarkers in melanoma patients treated with TIL. Knol AC; Nguyen JM; Pandolfino MC; Quéreux G; Brocard A; Peuvrel L; Saint-Jean M; Saiagh S; Khammari A; Dréno B PLoS One; 2012; 7(12):e48729. PubMed ID: 23284620 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Khammari A; Nguyen JM; Pandolfino MC; Quereux G; Brocard A; Bercegeay S; Cassidanius A; Lemarre P; Volteau C; Labarrière N; Jotereau F; Dréno B Cancer Immunol Immunother; 2007 Nov; 56(11):1853-60. PubMed ID: 17549472 [TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658 [TBL] [Abstract][Full Text] [Related]
13. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]. Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626 [TBL] [Abstract][Full Text] [Related]
14. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107 [TBL] [Abstract][Full Text] [Related]
16. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C; Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070 [TBL] [Abstract][Full Text] [Related]
17. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743 [TBL] [Abstract][Full Text] [Related]